Ceryvyn Therapeutics Limited · ASX:CYV
Ceryvyn Therapeutics — Investor Presentation (November 2026)
24 slides from Ceryvyn Therapeutics's investor presentation, Nov 17, 2026
Slide 1: Investor Information
rsonal use only Investor Information DR JEREMY LEVIN EXECUTIVE CHAIR A ND CEO November 2026
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation has been prepared by Ceryvyn Therapeutics Limited (ABN 32 006 340 567) (“Ceryvyn” or “Company”) to provide summary information about Ceryvyn and its affiliates and subsidiaries (the “Ceryvyn Group”) and their activities. The information contained in
Slide 3: Welcome to Ceryvyn
rsonal use only Welcome to Ceryvyn
Slide 4: Welcome to Ceryvyn
Welcome to Ceryvyn Translating unique science into breakthrough medicines rsonal use only Ceryvyn Therapeutics (ASX: CYV) is a clinical-stage Australian biopharmaceutical company developing medicines based on advances in human biology for patients with serious disease. • Focused on rare disease. Our
Slide 5: Why LAM offers a focused development opportunity
Why LAM offers a focused development opportunity rsonal use only Specialist centres provide a defined clinical development setting Established diagnostic criteria and biomarkers support patient identification Potential eligibility for orphan-drug incentive Established patient organisations may suppo
Slide 6: Ceryvyn's development strategy for LAM
Ceryvyn's development strategy for LAM rsonal use only Patent Focused clinical development protection and limited competition LAM Progressive lung disease affecting predominantly women CYV-101 CYV-101 is a clinical-stage biologic with extensive human experience and a focus on LAM CYV-101 Well-unders
Slide 7: Lymphangioleiomyomatosis (LAM)
rsonal use only Lymphangioleiomyomatosis (LAM)
Slide 8: Understanding Lymphangioleiomyomatosis
Understanding Lymphangioleiomyomatosis rsonal use only 19–23.5 women per million8 Genetic condition ~35 And up to 250,000 women worldwide Not caused by lifestyle choices Average age at diagnosis may be undiagnosed (estimate)6,7 • LAM is a low-grade neoplasm in the PEComa family, with abnormal cell g
Slide 9: Existing LAM patient journey
Existing LAM patient journey Current limitations and unmet clinical needs rsonal use only Early symptoms Non-specific breathlessness on exertion, cough and fatigue. Chest pain, lung collapse and/or coughing up blood. Misdiagnosis Often mistaken for asthma, emphysema, bronchitis or chronic obstructiv
Slide 10: Scientific rationale: Targeting VEGF-C/D pathway in LAM
Scientific rationale Targeting VEGF-C/D pathway in LAM rsonal use only When VEGF-C or VEGF-D bind to VEGF-C and VEGF-D are growth VEGFR-3, the lymphatic system “Lock and key” signals that tell lymphatic vessels VEGFR-3 is the receptor on lymphatic cells that receives gets a strong “expand and system
Slide 11: Ceryvyn Team
Ceryvyn THERAPEUTICS y Ceryvyn Team ersonal use onl
Slide 12: Focused, Efficient, Drug Developers
Focused, Efficient, Drug Developers Our Board Science Advisory Board rsonal use only Our Board brings extensive experience in drug development, Ceryvyn has brought together global thought leaders in LAM with biotechnology and VEGF biology, with a clear objective: advancing decades of clinical experi
Slide 13: Clinical Progress
rsonal use only Clinical Progress
Slide 14: Phase 1b/2a study of CYV-101 in LAM
Phase 1b/2a study of CYV-101 in LAM* rsonal use only OBJECTIVE Evaluate the safety, biological activity and potential clinical benefit of CYV-101 in patients with LAM PRIMARY FOCUS KEY 3- and 6- MONTH MEASURES EXPLORATORY MEASURE • Safety and tolerability • Hyperpolarised 129Xe MRI • Quantitative CT
Slide 15: Rigorous data-driven milestones
Rigorous data-driven milestones rsonal use only Preclinical inhalation and Early human Clinical proof-of-concept biology in large animal pharmacodynamic in LAM studies (PD) and tolerability IN PROGRESS GATE 1 GATE 2 GATE 3 Nebulisation performance VEGF-C/D modulation Lung function Lung delivery feas
Slide 16: Market Context
rsonal use only Market Context
Slide 17: Rare disease drugs with similar prevalence to LAM in the US
Rare disease drugs with similar prevalence to LAM in the US Annual price vs US prevalence 1 Drug US prevalence Annual WAC Total Annual Addressable Market rsonal use only Aqneursa 2,300 $404,000 $929,200,000 Vitrakvi 3,000 $394,000 $1,182,000,000 $700k Pombiliti + Opfolda Givlaari 3,500 $575,000 $2,0
Slide 18: Regulatory strategy
Regulatory strategy Ceryvyn may seek orphan designation when appropriate rsonal use only Orphan drug designation may unlock Market Potential post-approval exclusivity: 7 years in the US and 10 years in the EU, subject to conditions. exclusivity Japan extends its re-examination period. Australia offe
Slide 19: Corporate and financial overview
Corporate and financial overview Company name Financial position rsonal use only Ceryvyn Therapeutics A$27.5 million cash and cash equivalents (as at 30 September 2026) No debt, clean balance sheet ASX ticker CYV Based on current forecast, Ceryvyn has sufficient cash to support the three-stage LAM d
Slide 20: Conclusion
Conclusion rsonal use only CYV-101 is an existing biologic with a differentiated mechanism targeting VEGF-C and VEGF-D. LAM provides an opportunity to test the role of abnormal lymphatic signalling in a serious progressive disease. Our development program is designed to establish safety, biological
Slide 21: Appendix
Ceryvyn THERAPEUTICS y Appendix ersonal use onl
Slide 22: Citations
Citations rsonal use only • Baldwin M. CYV-101: A novel therapy for Wet AMD. Corporate Presentation (Ceryvyn Limited; ASX PDF). January 2017. p. 11 (slide 11) (states “CYV-101 (soluble VEGFR-3, VEGF-C/-D ‘Trap’)”). • Issaka, R. B., et al. (2009). Vascular Endothelial Growth Factors C and D Induce Pr
Slide 23: Citations: LAM disease facts
Citations: LAM disease facts rsonal use only • WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th edition, volume 5. Lyon: International Agency for Research on Cancer; 2021. • Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances S
Slide 24: Citations: economics, pricing and regulation
Citations: economics, pricing and regulation rsonal use only • Jayasundara K, et al. Estimating the clinical cost of drug development for orphan versus non -orphan drugs. Orphanet J Rare Dis. 2019;14:12. doi:10.1186/s13023-018-0990-4. • Michaeli T, Jürges H, Michaeli DT. FDA approval, clinical trial
Ceryvyn Therapeutics — Investor Presentation (November 2026) on 6ix